Journal of Nanobiotechnology · 2021 · 92 citations · 47 references
PharmacyInfectious DiseasesPharmaceuticsDrug DeliveryInflammationNanoparticle Drug DeliveryAntiviral TherapyNanocarriers For TherapeuticsNanomaterials For Drug DeliveryNanomedicineNanoparticle Delivery SystemsNanoparticle FormulationsAntiviral TreatmentCytokine Storm SyndromeDrug Delivery NanocarriersMacrophage ImmunomodulationNanocarriersNanoparticle-based Macrophage TargetingProinflammatory Cytokine ModulationTargeted Antiviral Therapy
BACKGROUND: The worldwide pandemic of COVID-19 remains a serious public health menace as the lack of efficacious treatments. Cytokine storm syndrome (CSS) characterized with elevated inflammation and multi-organs failure is closely correlated with the bad outcome of COVID-19. Hence, inhibit the process of CSS by controlling excessive inflammation is considered one of the most promising ways for COVID-19 treatment. RESULTS: Here, we developed a biomimetic nanocarrier based drug delivery system against COVID-19 via anti-inflammation and antiviral treatment simultaneously. Firstly, lopinavir (LPV) as model antiviral drug was loaded in the polymeric nanoparticles (PLGA-LPV NPs). Afterwards, macrophage membranes were coated on the PLGA-LPV NPs to constitute drugs loaded macrophage biomimetic nanocarriers (PLGA-LPV@M). In the study, PLGA-LPV@M could neutralize multiple proinflammatory cytokines and effectively suppress the activation of macrophages and neutrophils. Furthermore, the formation of NETs induced by COVID-19 patients serum could be reduced by PLGA-LPV@M as well. In a mouse model of coronavirus infection, PLGA-LPV@M exhibited significant targeted ability to inflammation sites, and superior therapeutic efficacy in inflammation alleviation and tissues viral loads reduction. CONCLUSION: Collectively, such macrophage biomimetic nanocarriers based drug delivery system showed favorable anti-inflammation and targeted antiviral effects, which may possess a comprehensive therapeutic value in COVID-19 treatment.
47
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang, Yeming Wang, Xingwang Li et al. · The Lancet · 2020 · 51.8K citations · Full text
Clinical Characteristics of Coronavirus Disease 2019 in China
Wei‐jie Guan, Zhengyi Ni, Yu Hu et al. · New England Journal of Medicine · 2020 · 31.2K citations · Full text
Veterinary Medicine, Infectious Diseases, Internal Medicine +10
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Bin Cao, Yeming Wang, Danning Wen et al. · New England Journal of Medicine · 2020 · 5.5K citations · Full text